EUVIMED · CrossrefJournal
ESMO Open
ISSN 2059-7029 · Elsevier BV
Latest articles
APOBEC3-mediated therapy resistance and immunogenicity in solid tumors: from genomic scars to therapeutic vulnerabilities
Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results
Rethinking cardiac monitoring in patients receiving trastuzumab-based HER2-directed therapies for breast cancer: a meta-analysis and cost-effectiveness analysis
Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial
Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer
Patterns of central nervous system and leptomeningeal involvement in advanced breast cancer with invasive lobular histology: a large multicenter study with a focus on estrogen receptor-positive/HER2-negative disease
Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas
“Our patients deserve better”—roadblocks to optimal care in biliary malignancies
Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer
The cost of intensification in high-risk non–muscle-invasive bladder cancer
Phase II study of magrolimab combination therapies in patients with advanced triple-negative breast cancer
Structured physical activity in high-risk stage II and stage III colon cancer: tertiary prevention of colorectal cancer recurrence or primary prevention in a population at high risk of secondary cancers?
Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measure
Pembrolizumab plus FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: analysis of the FLOT cohort from the phase 3 KEYNOTE-585 study
Parity, breastfeeding, and reproductive timing are associated with tumour-infiltrating lymphocytes in hormone receptor-negative breast cancer: a population-based cohort study
Identification and prognostic value of non-hotspot POLE exonuclease domain mutations in endometrial cancer
Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project
Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy
Mapping off-label use and reimbursement pathways for oncology drugs in The Netherlands: a cross-sectional observational study
Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO)
Adjuvant therapy for RCC: considerations beyond survival metrics
Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis
Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials
Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II trial (CA209-8M4)
A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study
Real-world adoption of circulating tumor DNA testing and adjuvant treatment decisions after radical cystectomy for muscle-invasive bladder cancer
daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma
Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study
EUVIMED